Article info
Laboratory science
Compatibility of recombinant tissue plasminogen activator (rtPA) and aflibercept or ranibizumab coapplied for neovascular age-related macular degeneration with submacular haemorrhage
- Correspondence to Professor Alexa Klettner, Department of Ophthalmology, University of Kiel, University Medical Center Schleswig-Holstein, Arnold-Heller Str. 3, Haus 25, Kiel D-24105, Germany; aklettner{at}auge.uni-kiel.de
Citation
Compatibility of recombinant tissue plasminogen activator (rtPA) and aflibercept or ranibizumab coapplied for neovascular age-related macular degeneration with submacular haemorrhage
Publication history
- Received November 26, 2014
- Revised January 6, 2015
- Accepted February 9, 2015
- First published March 4, 2015.
Online issue publication
May 20, 2015
Article Versions
- Previous version (4 March 2015).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions